COMMUNIQUÉS West-GlobeNewswire

Kymera Therapeutics to Participate in Upcoming June Investor Conferences
29/05/2025
WATERTOWN, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological [...]
Syndax Announces Participation in June Investor Conferences
29/05/2025
NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief [...]
Axsome Therapeutics to Participate in Upcoming Investor Conferences
29/05/2025
NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will [...]
La Croix-Rouge canadienne vient en aide aux personnes touchées par les feux de forêt au Manitoba
29/05/2025
Service d’inscription offert et appel de fonds lancé OTTAWA, Ontario, 29 mai 2025 (GLOBE NEWSWIRE) -- La Croix-Rouge canadienne collabore présentement avec les autorités dirigeantes des communautés autochtones et tous [...]
Canadian Red Cross supporting people impacted by Manitoba wildfires
29/05/2025
Registration Services Opened and Appeal Launched OTTAWA, Ontario, May 29, 2025 (GLOBE NEWSWIRE) -- The Canadian Red Cross is currently working alongside Indigenous community leadership and all levels of government to [...]
Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
29/05/2025
DALLAS, May 28, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies [...]
Nxera Pharma Notes Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025
29/05/2025
Tokyo, Japan and Cambridge, UK, 29 May 202 5 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) notes that Neurocrine Biosciences, Inc. announced that it had presented new positive data from the Phase 2 study [...]
argenx Announces Results of Annual General Meeting of Shareholders
28/05/2025
May 28, 2025 – 10:01 PM C ET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, [...]
Corvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference
28/05/2025
SOUTH SAN FRANCISCO, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one [...]
Century Therapeutics Announces Two Upcoming Presentations at the EULAR 2025 Congress
28/05/2025
PHILADELPHIA, May 28, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in [...]
Taysha Gene Therapies Announces Pivotal Part B Trial Design Details for TSHA-102 in Rett Syndrome Enabled by IRSF Natural History Data and Positive Clinical Data from Part A of the REVEAL Adult/Adolescent and Pediatric Trials Evaluating TSHA-102
28/05/2025
Natural history data analysis established patients ≥ six years of age are in developmental plateau, with a ~0% likelihood of gaining/regaining developmental milestones across the core functional domains of Rett syndrome [...]
EyePoint Announces Participation at Upcoming Investor Conferences
28/05/2025
WATERTOWN, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with [...]
Disc Medicine to Participate in Upcoming Investor Conferences
28/05/2025
WATERTOWN, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for [...]
Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
28/05/2025
DALLAS, May 28, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies [...]
ORIC® Pharmaceuticals Announces Potentially Best-In-Class Preliminary Efficacy and Safety Data from Ongoing Phase 1b Trial of ORIC-944 in Combination with AR Inhibitors for the Treatment of Patients with mCRPC
28/05/2025
Broad and deep PSA responses achieved, with 59% PSA50 response rate (confirmed rate of 47%, and one additional response pending confirmation) and 24% PSA90 response rate (all confirmed) in patients with mCRPC PSA [...]
Sanuwave Health Appoints Greg Bazar to Board of Directors
28/05/2025
Bazar brings decades of experience in engineering, computer science and cyber security, AI, and business intelligence over a career of building successful companies EDEN PRAIRIE, Minn., May 28, 2025 (GLOBE NEWSWIRE) -- [...]
Artiva Biotherapeutics to Participate in the Jefferies Global Healthcare Conference
28/05/2025
SAN DIEGO, May 28, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients [...]
Sana Biotechnology to Present at June 2025 Investor Conferences
28/05/2025
SEATTLE, May 28, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations [...]
ORIC® Pharmaceuticals Announces $125 Million Private Placement Financing
28/05/2025
Financing led by SR One and includes participation from new and existing investors, including Point72, Viking Global Investors, Venrock Healthcare Capital Partners, New Enterprise Associates (NEA), Nextech, Vivo Capital [...]

Pages